Tetraphase CEO touts trou­bled an­tibi­ot­ic’s peak sales po­ten­tial; Copen­hagen wants to host the EMA

• Shares of Tetraphase Phar­ma­ceu­ti­cals $TTPH have dropped more than 90% off their high and the lead an­tibi­ot­ic failed a Phase III, but CEO Guy Mac­don­ald is still tout­ing er­ava­cy­cline’s com­mer­cial po­ten­tial. The an­tibi­ot­ic could earn $700 mil­lion a year, he told Reuters. “We just need the da­ta,” Mac­don­ald said. And how.

• Por­to­la $PT­LA says that the FDA doesn’t plan to hold an Ad­Comm meet­ing for be­trix­a­ban, their Fac­tor Xa in­hibitor an­ti­co­ag­u­lant. “Based on the APEX da­ta, we re­main con­fi­dent in the po­ten­tial for be­trix­a­ban to be ap­proved as the first an­ti­co­ag­u­lant for ex­tend­ed-du­ra­tion VTE pro­phy­lax­is in high-risk acute med­ical­ly ill pa­tients,” said John T. Cur­nutte, MD, PhD, ex­ec­u­tive vice pres­i­dent, re­search and de­vel­op­ment, at Por­to­la. Por­to­la was slammed last year when the FDA re­ject­ed its an­ti-an­ti­co­ag­u­lant an­dex­anet al­fa.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER